Overview

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma

Status:
Not yet recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This phase II trial tests whether atezolizumab with or without selinexor works to shrink tumors in patients with alveolar soft part sarcoma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may help keep cancer cells from growing and may kill them. Giving atezolizumab with or without selinexor may help shrink tumors and stabilize the cancer in patients with alveolar soft part sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Atezolizumab